Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
1.57
USD
|
+1.95%
|
|
-3.68%
|
-5.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
392.1
|
199.8
|
276.4
|
169.2
|
71.91
|
98.48
|
-
|
-
|
Enterprise Value (EV)
1 |
392.1
|
199.8
|
276.4
|
169.2
|
71.91
|
98.48
|
98.48
|
98.48
|
P/E ratio
|
-4.57
x
|
-3.94
x
|
-6.42
x
|
-2.87
x
|
-1.2
x
|
-1.37
x
|
-1.02
x
|
-3.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
18.4
x
|
33.8
x
|
71.9
x
|
-
|
7.3
x
|
1.12
x
|
EV / Revenue
|
-
|
-
|
18.4
x
|
33.8
x
|
71.9
x
|
-
|
7.3
x
|
1.12
x
|
EV / EBITDA
|
-6.78
x
|
-3.95
x
|
-6.43
x
|
-2.84
x
|
-1.18
x
|
-1.82
x
|
-2.62
x
|
1.88
x
|
EV / FCF
|
-7.6
x
|
-3.94
x
|
5.34
x
|
-3.21
x
|
-
|
-1.97
x
|
-2.15
x
|
2.4
x
|
FCF Yield
|
-13.1%
|
-25.4%
|
18.7%
|
-31.2%
|
-
|
-50.7%
|
-46.6%
|
41.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
24,493
|
29,823
|
42,198
|
42,716
|
43,059
|
62,727
|
-
|
-
|
Reference price
2 |
16.01
|
6.700
|
6.550
|
3.960
|
1.670
|
1.570
|
1.570
|
1.570
|
Announcement Date
|
3/6/20
|
3/29/21
|
3/24/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
15
|
5
|
1
|
-
|
13.5
|
87.55
|
EBITDA
1 |
-57.84
|
-50.61
|
-42.98
|
-59.55
|
-61.01
|
-54.2
|
-37.6
|
52.4
|
EBIT
1 |
-57.88
|
-50.71
|
-43.07
|
-59.64
|
-61.1
|
-61.1
|
-84.63
|
-20.9
|
Operating Margin
|
-
|
-
|
-287.15%
|
-1,192.84%
|
-6,109.8%
|
-
|
-626.93%
|
-23.87%
|
Earnings before Tax (EBT)
1 |
-55.28
|
-49.98
|
-42.85
|
-58.39
|
-59.68
|
-59.72
|
-83.83
|
-18.5
|
Net income
1 |
-55.23
|
-49.97
|
-42.85
|
-58.39
|
-59.68
|
-59.72
|
-82.88
|
-16.6
|
Net margin
|
-
|
-
|
-285.69%
|
-1,167.76%
|
-5,968.5%
|
-
|
-613.97%
|
-18.96%
|
EPS
2 |
-3.500
|
-1.700
|
-1.020
|
-1.380
|
-1.390
|
-1.150
|
-1.545
|
-0.5200
|
Free Cash Flow
1 |
-51.56
|
-50.73
|
51.78
|
-52.74
|
-
|
-49.9
|
-45.9
|
41.1
|
FCF margin
|
-
|
-
|
345.17%
|
-1,054.82%
|
-
|
-
|
-340.03%
|
46.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
78.44%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/29/21
|
3/24/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
1.5
|
3.5
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.7667
|
EBITDA
1 |
-14.25
|
-16.9
|
-14.02
|
-16.78
|
-15
|
-13.74
|
-15.48
|
-16.41
|
-15.34
|
-13.77
|
-12.8
|
-13
|
-13.7
|
-14.9
|
-
|
EBIT
1 |
-14.27
|
-16.92
|
-14.05
|
-16.81
|
-15.03
|
-13.76
|
-15.5
|
-16.44
|
-15.36
|
-13.8
|
-13.02
|
-13.88
|
-15.22
|
-18.98
|
-20.85
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,002%
|
-393.11%
|
-1,550.2%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,719.55%
|
Earnings before Tax (EBT)
1 |
-14.22
|
-16.88
|
-14.01
|
-16.65
|
-14.56
|
-13.18
|
-14.95
|
-16.04
|
-15.08
|
-13.61
|
-12.86
|
-13.75
|
-15.14
|
-18.92
|
-20.92
|
Net income
1 |
-14.22
|
-16.88
|
-14.01
|
-16.65
|
-14.56
|
-13.18
|
-14.95
|
-16.04
|
-15.08
|
-13.61
|
-12.86
|
-13.75
|
-15.14
|
-18.92
|
-20.92
|
Net margin
|
-
|
-
|
-
|
-
|
-970.4%
|
-376.49%
|
-1,495%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,729.34%
|
EPS
2 |
-0.3400
|
-0.4000
|
-0.3300
|
-0.3900
|
-0.3400
|
-0.3100
|
-0.3500
|
-0.3700
|
-0.3500
|
-0.3200
|
-0.2600
|
-0.2625
|
-0.2900
|
-0.3700
|
-0.3400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/24/22
|
5/12/22
|
8/10/22
|
11/10/22
|
3/29/23
|
5/11/23
|
8/10/23
|
11/13/23
|
3/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.6
|
-50.7
|
51.8
|
-52.7
|
-
|
-49.9
|
-45.9
|
41.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.41
|
-
|
-
|
0.27
|
-
|
5.1
|
10.1
|
15.1
|
Capex / Sales
|
-
|
-
|
-
|
5.44%
|
-
|
-
|
74.82%
|
17.25%
|
Announcement Date
|
3/6/20
|
3/29/21
|
3/24/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
1.57
USD Average target price
10.5
USD Spread / Average Target +568.79% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.99% | 96.6M | | -2.63% | 103B | | +1.62% | 95.28B | | +1.46% | 22.15B | | -16.67% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -13.21% | 16.05B | | +5.41% | 13.68B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|